Hydrolysable tannins as a potential therapeutic drug for the human fibrosis-associated disease

Drug Dev Res. 2023 Sep;84(6):1096-1113. doi: 10.1002/ddr.22089. Epub 2023 Jun 29.

Abstract

Fibrosis is a pathological change with abnormal tissue regeneration due to a response to persistent injury, which is extensively related to organ damage and failure, leading to high morbidity and mortality worldwide. Although the pathogenesis of fibrosis has been comprehensively elucidated, there are few effective therapies for treating fibrotic diseases. Natural products are increasingly regarded as an effective strategy for fibrosis with numerous favorable functions. Hydrolysable tannins (HT) are a type of natural products that have the potential to treat the fibrotic disease. In this review, we describe some biological activities and the therapeutic prospects of HT in organ fibrosis. Furthermore, the underlying mechanisms of inhibition of HT on fibrotic organs in relation to inflammation, oxidative stress, epithelial-mesenchymal transition, fibroblast activation and proliferation, and extracellular matrix accumulation are discussed. Understanding the mechanism of HT against fibrotic diseases will provide a new strategy for the prevention and attenuation of fibrosis progression.

Keywords: biological activities; fibrosis; hydrolysable tannins; mechanisms of fibrosis; therapeutic prospects.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Products*
  • Extracellular Matrix / pathology
  • Fibrosis
  • Humans
  • Hydrolyzable Tannins*
  • Inflammation / pathology

Substances

  • Hydrolyzable Tannins
  • Biological Products